ReviewHeart failure reviews2026
Myocardial remodeling in valvular heart disease: pathophysiology, multimodality imaging and treatment implications.
Review in Heart failure reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valvular cardiomyopathy has emerged as a key concept linking valvular heart disease (VHD) with myocardial remodeling and the development of heart failure (HF). This state-of-the-art review provides a comprehensive overview of pathophysiological mechanisms, multimodality imaging, and implication for valve interventions across the spectrum of VHD. We systematically address HF in the context of aortic valve disease, including aortic stenosis and aortic regurgitation, mitral valve disease with a particular focus on mitral regurgitation, and tricuspid valve regurgitation. For each valvular lesion, we integrate evidence on pathophysiological mechanisms on myocardial (mal)adaptation leading to myocardial fibrosis and ultimately HF and death. Additionally, we highlight the role of multimodality imaging for early detection of myocardial remodeling and discuss implications for patient selection and timing of valve interventions. Beyond single-valve disease, we further explore the complex interplay of multiple and mixed valvular heart disease and review emerging data on the interaction between VHD and cardiac amyloidosis, an increasingly recognized and clinically relevant overlap. Overall, this state-of-the-art review underscores that outcomes in VHD are not solely determined by severity of valvular lesions but critically depend on the extent of associated myocardial damage. A deeper understanding of valvular cardiomyopathy may improve risk stratification, refine patient selection, and support the implementation of tailored therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.